Kate Hanrott
Kate Hanrott has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Virginia Norris
EpiEndo Pharmaceuticals, Reykjavík, Iceland
3 shared publicationsAlbertus Beishuizen
Intensive Care Center, Medisch Spectrum Twente, Enschede, Netherlands
1 shared publication- Anthony Cahn
GlaxoSmithKline, Stevenage, United Kingdom
1 shared publication Anubha Gupta
GSK Medicines Research Centre, Stevenage, UK
1 shared publicationBjörn Schultze
CTC Clinical Trial Consultants AB Uppsala Sweden
1 shared publicationBruno François
Service Réanimation Polyvalente and Inserm CIC1435 & UMR1092, CHU Limoges, Limoges Cedex, France
1 shared publication
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8728
Impact of the anti-inflammatory macrolide glasmacinal on the gut microbiota of healthy adults: an open-label trial
Glasmacinal (EP395) is an oral macrolide, with immunomodulatory properties like antibiotic macrolides (such as azithromycin), but with negligible in vitro antimicrobial activity, which is being developed as a potential treatment to reduce exacerbations in respiratory conditions. In an open-label healthy participant trial (ClinicalTrials.gov: NCT06118684), with the primary objective of assessing potential drug-drug interactions of glasmacinal, faecal samples were collected to evaluate the impact on the gut microbiota of daily doses of glasmacinal for 2 weeks, using both phenotypic and 16S rRNA gene sequencing. Glasmacinal produced modest effects: reduced phylogenetic richness (p < 0.0001), but not evenness, and altered beta-diversity (PERMANOVA R 2 = 0.104 p.adj=0.0018 after 1 week, and R 2 = 0.059, p.adj=0.028 after 2 weeks) with reductions in Clostridiaceae , Enterobacteriaceae , and Sutterellaceae abundance. The community shift was approximately 10% after 1-week glasmacinal, and 6% after 2-weeks. With quantitative culture, only Enterobacterales was impacted. No increase or selection of resistance to azithromycin in Enterobacterales and Bacteroides , nor increase in Candida spp . or Clostridioides difficile , were detected. Overall, glasmacinal induced limited restructuring of the gut microbiome (without the defining hallmarks of antibiotic-like dysbiosis), core anaerobic phyla of the gut (Firmicutes and Bacteroidetes) were preserved, and there was no selection of antimicrobial resistance.
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8728
Open AccessImpact of the anti-inflammatory macrolide glasmacinal on the gut microbiota of healthy adults: an open-label trial
Glasmacinal (EP395) is an oral macrolide, with immunomodulatory properties like antibiotic macrolides (such as azithromycin), but with negligible in vitro antimicrobial activity, which is being developed as a potential treatment to reduce exacerbations in respiratory conditions. In an open-label healthy participant trial (ClinicalTrials.gov: NCT06118684), with the primary objective of assessing potential drug-drug interactions of glasmacinal, faecal samples were collected to evaluate the impact on the gut microbiota of daily doses of glasmacinal for 2 weeks, using both phenotypic and 16S rRNA gene sequencing. Glasmacinal produced modest effects: reduced phylogenetic richness (p < 0.0001), but not evenness, and altered beta-diversity (PERMANOVA R 2 = 0.104 p.adj=0.0018 after 1 week, and R 2 = 0.059, p.adj=0.028 after 2 weeks) with reductions in Clostridiaceae , Enterobacteriaceae , and Sutterellaceae abundance. The community shift was approximately 10% after 1-week glasmacinal, and 6% after 2-weeks. With quantitative culture, only Enterobacterales was impacted. No increase or selection of resistance to azithromycin in Enterobacterales and Bacteroides , nor increase in Candida spp . or Clostridioides difficile , were detected. Overall, glasmacinal induced limited restructuring of the gut microbiome (without the defining hallmarks of antibiotic-like dysbiosis), core anaerobic phyla of the gut (Firmicutes and Bacteroidetes) were preserved, and there was no selection of antimicrobial resistance.
- Open Access
- 17 March 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (7) , 2349-2363
Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions
Aims: This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI). Methods: The FIH trial was a randomized, double‐blind, placebo‐controlled trial of single (20–750 mg) and multiple (120–375 mg daily for 28 days) doses of glasmacinal. The DDI trial was an open‐label assessment of the effect of verapamil (moderate CYP3A4 inhibitor and P‐gp inhibitor) on the PK of glasmacinal, and the effect of glasmacinal on the PK of midazolam (CYP3A4 substrate) and digoxin (P‐gp substrate). Results: No SAEs or severe AEs occurred, and no AEs considered related to glasmacinal led to withdrawal. Glasmacinal was rapidly absorbed, reaching peak plasma concentrations at ~4 h post‐dose and a terminal half‐life ~70 h. Glasmacinal systemic exposure ( C max and AUC 0–inf ) was reduced by one third when administered after food (300‐mg single dose, parallel group comparison). Co‐administration of glasmacinal with verapamil increased glasmacinal exposure ( C max 1.70‐fold [90% CI: 1.52, 2.39], AUC 0–inf 2.41‐fold [90% CI: 2.18, 2.82]). Glasmacinal modestly increased exposure to midazolam ( C max 1.26‐fold [90% CI: 1.12, 1.49], AUC 0–inf 1.54‐fold [90% CI: 1.33, 1.89]) and digoxin ( C max 1.38‐fold [90% CI: 1.22, 1.81] and AUC 0–inf 1.37‐fold [90% CI: 1.26, 1.52]). Conclusions: Glasmacinal was well tolerated in single doses up to 750 mg and repeat doses up to 375 mg. Glasmacinal may be a victim of selected drugs that impact CYP3A4 and/or P‐gp but is unlikely to be a perpetrator of clinically relevant DDIs.
- 17 March 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (7) , 2349-2363
Open AccessEarly clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions
Aims: This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI). Methods: The FIH trial was a randomized, double‐blind, placebo‐controlled trial of single (20–750 mg) and multiple (120–375 mg daily for 28 days) doses of glasmacinal. The DDI trial was an open‐label assessment of the effect of verapamil (moderate CYP3A4 inhibitor and P‐gp inhibitor) on the PK of glasmacinal, and the effect of glasmacinal on the PK of midazolam (CYP3A4 substrate) and digoxin (P‐gp substrate). Results: No SAEs or severe AEs occurred, and no AEs considered related to glasmacinal led to withdrawal. Glasmacinal was rapidly absorbed, reaching peak plasma concentrations at ~4 h post‐dose and a terminal half‐life ~70 h. Glasmacinal systemic exposure ( C max and AUC 0–inf ) was reduced by one third when administered after food (300‐mg single dose, parallel group comparison). Co‐administration of glasmacinal with verapamil increased glasmacinal exposure ( C max 1.70‐fold [90% CI: 1.52, 2.39], AUC 0–inf 2.41‐fold [90% CI: 2.18, 2.82]). Glasmacinal modestly increased exposure to midazolam ( C max 1.26‐fold [90% CI: 1.12, 1.49], AUC 0–inf 1.54‐fold [90% CI: 1.33, 1.89]) and digoxin ( C max 1.38‐fold [90% CI: 1.22, 1.81] and AUC 0–inf 1.37‐fold [90% CI: 1.26, 1.52]). Conclusions: Glasmacinal was well tolerated in single doses up to 750 mg and repeat doses up to 375 mg. Glasmacinal may be a victim of selected drugs that impact CYP3A4 and/or P‐gp but is unlikely to be a perpetrator of clinically relevant DDIs.
- Open Access
- 4 December 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients
Background: Macrolide antibiotics have immunomodulatory activity and when taken chronically reduce exacerbations of COPD. However, chronic use can cause bacterial resistance. EP395 (glasmacinal), a novel macrolide, is being developed as a treatment to reduce exacerbations of COPD without inducing antimicrobial resistance. Methods: In this double-blind, placebo-controlled, phase 2a trial ( NCT05572333 ), patients (≥45 years old, diagnosed with COPD for ≥2 years and stable on at least one maintenance inhaled therapy) were randomised (2:1) to EP395 or placebo daily for 12 weeks. The primary objective was safety, with key secondary objectives assessing pharmacodynamic effects of EP395. Results: A total of 61 patients were randomised (42 EP395, 19 placebo). A 12-week course of EP395 was well tolerated: no serious adverse events were considered related to EP395, and adverse events occurred in similar proportions in both groups (64.3% EP395, 63.2% placebo). Four patients were withdrawn due to adverse events (three EP395, one placebo). Sputum neutrophil elastase and myeloperoxidase, mediators of neutrophil activation, were reduced with EP395 (treatment difference (log scale): neutrophil elastase −0.415 ng·mL −1 , 95% CI −0.787 to −0.043 ng·mL −1 , p=0.030; myeloperoxidase −0.282 ng·mL −1 , 95% CI −0.640 to 0.076 ng·mL −1 , p=0.119). Relative changes in neutrophil elastase and myeloperoxidase from baseline with EP395 were 66% and 75%, respectively, of those observed with placebo. Exploratory 16S rRNA sequencing of sputum showed EP395 had no detectable effect on the lung microbiome, including the proportion of pathogenic Proteobacteria species. Conclusion: In patients with stable COPD, EP395 for 12 weeks was well tolerated, demonstrated selective anti-inflammatory activity and had no detectable effect on the lung microbiome.
- 4 December 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Open AccessA randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients
Background: Macrolide antibiotics have immunomodulatory activity and when taken chronically reduce exacerbations of COPD. However, chronic use can cause bacterial resistance. EP395 (glasmacinal), a novel macrolide, is being developed as a treatment to reduce exacerbations of COPD without inducing antimicrobial resistance. Methods: In this double-blind, placebo-controlled, phase 2a trial ( NCT05572333 ), patients (≥45 years old, diagnosed with COPD for ≥2 years and stable on at least one maintenance inhaled therapy) were randomised (2:1) to EP395 or placebo daily for 12 weeks. The primary objective was safety, with key secondary objectives assessing pharmacodynamic effects of EP395. Results: A total of 61 patients were randomised (42 EP395, 19 placebo). A 12-week course of EP395 was well tolerated: no serious adverse events were considered related to EP395, and adverse events occurred in similar proportions in both groups (64.3% EP395, 63.2% placebo). Four patients were withdrawn due to adverse events (three EP395, one placebo). Sputum neutrophil elastase and myeloperoxidase, mediators of neutrophil activation, were reduced with EP395 (treatment difference (log scale): neutrophil elastase −0.415 ng·mL −1 , 95% CI −0.787 to −0.043 ng·mL −1 , p=0.030; myeloperoxidase −0.282 ng·mL −1 , 95% CI −0.640 to 0.076 ng·mL −1 , p=0.119). Relative changes in neutrophil elastase and myeloperoxidase from baseline with EP395 were 66% and 75%, respectively, of those observed with placebo. Exploratory 16S rRNA sequencing of sputum showed EP395 had no detectable effect on the lung microbiome, including the proportion of pathogenic Proteobacteria species. Conclusion: In patients with stable COPD, EP395 for 12 weeks was well tolerated, demonstrated selective anti-inflammatory activity and had no detectable effect on the lung microbiome.
- Open Access
- 2 February 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 61 (2) , 2101870
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)
Background: Granulocyte–macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19.Methods: In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18–79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care (NCT04376684). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28.Results: In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28versus67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI −0.8–11.4%, p=0.09). A nominally significant model-adjusted difference of 19.1% (95% CI 5.2–33.1%, p=0.009) was observed in the predefined 70–79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI −9.3–11.2%, p=0.86). Compared with placebo, otilimab resulted in lower serum concentrations of key inflammatory markers, including the putative pharmacodynamic biomarker CC chemokine ligand 17, indicative of GM-CSF pathway blockade. Adverse events were comparable between groups and consistent with severe COVID-19.Conclusions: There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.
- 2 February 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 61 (2) , 2101870
Open AccessA randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)
Background: Granulocyte–macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19.Methods: In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18–79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care (NCT04376684). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28.Results: In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28versus67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI −0.8–11.4%, p=0.09). A nominally significant model-adjusted difference of 19.1% (95% CI 5.2–33.1%, p=0.009) was observed in the predefined 70–79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI −9.3–11.2%, p=0.86). Compared with placebo, otilimab resulted in lower serum concentrations of key inflammatory markers, including the putative pharmacodynamic biomarker CC chemokine ligand 17, indicative of GM-CSF pathway blockade. Adverse events were comparable between groups and consistent with severe COVID-19.Conclusions: There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.